Main Menu

Show posts

This section allows you to view all posts made by this member. Note that you can only see posts made in areas you currently have access to.

Show posts Menu

Topics - Flux

Media/Resources / New 5-MeO-DMT Film
October 09, 2020, 03:24:37 AM
There is a new film about 5-MeO being released and promoted. I was wondering if anyone knows the folks behind it and of anyone has had a chance to watch it yet (it is very new). Perhaps the producers, directors are members here and could tell us all a little more about it ?

cheers all :)

Dobkin de Rios, M. 1974. The influence of psychotropic flora and fauna on Maya religion. Current Anthropology 15: 147-164.

For those who have not read this yet, do enjoy this wonderful article from regular 5Hive contributor Bancopuma - gracias hermano
Science / Bufo-cybin ?
January 24, 2018, 02:45:17 AM
Well this got my attention... (although I cannot imagine anyone having enough 5-MeO-DMT to explore this on anything other than a micro scale;

" [/size]Alexander Shulgin[/size] has explained that it could be possible to cultivate 4-HO-5-MeO-DMT in [/size]psilocybin mushrooms[/size] by adding 5-MeO-DMT to the growing substrate of the fungus".
January 09, 2018, 07:20:50 AM

The overwhelming somatic aspect of the 5-MeO-DMT (and other psychedelic medicine) experience is something that I continue to attempt to understand in some way in order to harness, utilise and apply the experience and concept to everyday life somehow. So much focus is given to the psychological aspects of psychedelics and little to the kinetically sensory facets. As 5-MeO-DMT is unique in its targeting, aligning, clearing and releasing of what is often perceived as 'the energetic body' and exhibits time and time again a fury of energy either pouring through the physical bodily vessel or arising out of it, it seems to me only causal that many individuals would interpret their experiences through the concept of Kundalini (awakening or otherwise).

I hear the term Kundalini so often and used in many different ways and contexts, it can often seems like an ambiguous 'new-agey' marketing variation on other practices like Yoga, Tantra and the like. Yet nonetheless, I have visualised, felt and witnessed in others what appears to quite specifically be a rising of a serpentine like energy from the base of the spine (which is about as far as my knowledge and understanding of the phenomenon extends).

I would like to start this thread with some resources that may help to build a common framework for what Kundalini is in the context of the psychedelic experience, and of course particularly 5-MeO-DMT to subsequently gather knowledge about the intersection between the two. I therefore extend a welcome to forum members better versed, studied or practised in the Kundalini phenomenon, (its traditional/mythological origins, theoretical applications, and disciplinary devotions) to contribute to this understanding ...or for anyone to simply share any anecdotal experiences.

Kundalini Awakening Systems 1, Drugs & Kundalini

Psychedelic Drugs & Kundalini, by Donald J. DeGracia, Ph.D.

Psychedelics and Kundalini awakening,

Do Psychedelic Drugs Mimic Awakened Kundalini? Hallucinogen Survey Results, by Donald J. DeGracia, Council for Spiritual Practices,

Extended Kundalini Awakening LSD by Mahan Atma,

Insight Practices, Kundalini, and Psychedelics Safety, Dharma Overground,

Psychedelics and Kundalini Energy, Bluelight,

With Gracious Blessings,


A robust community discussion on the role, importance and shape of 5-MeO-DMT in modern culture from the Somara Shamanic Medicine Forum, Feb, 2016. hosted by Rak Razam with guests Shannon Kempster, Maya Waken, Dean Jefferys, Dan Schreiber and Jewelli Deva.

What is the connection between the Mexican Sonoran desert toad and the legendary yagé of Amazonian tribes? What role does bufotenine play in the 5-MeO neurochemical cocktail in plants and toads? Unified field. Source consciousness. Home: what celestial cartography do these catalysts reveal? Is this the return of DreaMTime consciousness? Are there any significant differences between synthetic and organic 5-MeO, or plant-based and toad-based 5-MeO? Do repeated doses of 5-MeO make one more sensitive to the medicine and to the ceremony of life itself? How do we keep open the endogenous pathways that the medicine can reveal? Recorded and shared by Kent Holloway. With thanks to Somara:
Season 2 of Hamilton Morris's series Pharmacopia is out and Episode 1 of this second season features our friend and ally Bufo Alvarius in 'The Psychedelic Toad'.

As these documentaries inevitably feature one particular practitioner, this episode is no exception and some have already noted concerns around certain aspects of the ceremony depicted. These elements aside, this episode goes into some of the cultural history of 5-MeO (and the documents mentioned can be found in our 'Media & Resources' section here under Articles), and like the entire series is well researched and Hamilton approaches these medicines with great respect and a deep curiosity.

The episode is geo-blocked meaning it can only be viewed from the US without a VPN installed (this is a simple one download step and is a useful tool to have).
Haven't listened to this yet and not even familiar with The Oracle frequency but the difference between 5-MeO-DMT and n-n-DMT is a question that ariese a lot within psychedelic discourse, so check it out guys and see if you think the descriptions are apt.

I know Terence McKenna attempted (albeit briefly) to address the difference years back but given I don't think he ever had a full release dose of 5-MeO in within toad venom or synthetic form (can someone confirm or correct me on this) his description was somewhat wanting.
Articles / Toad Licking Blues
August 29, 2017, 04:45:12 AM
A very interesting chapter that provides somewhat of a cultural history of toad use in the West;

Lyttle, T 2009, 'Toad Licking Blues', in 'You Are STILL Being Lied To: The NEW Disinformation Guide to Media Distortion, Historical Whitewashes and Cultural Myths', Ross Kick (ed.), The Disinformation Guides Ltd.

Law / Lore / Legal Status of 5-MeO-DMT by Country
May 30, 2017, 08:32:06 PM
This information is a summary of data gathered from, its site visitors, government documents, websites, and other resources. We are not lawyers and cannot guarantee the accuracy of the information provided here. We do our best to keep this information correct and up-to-date, but laws are complex and constantly changing. Laws may also vary from one jurisdiction to another (county, state, country, etc)...this list is not comprehensive.

If any members have information about the legal status of this substance in any other country, please let us know so that we can improve the range and accuracy of this data.



5-MeO-DMT is a schedule 1 controlled substance in all United States as of January 2011, if you have information about the legal status of this substance in any other U.S. state please feel free to comment and we will include it here


As a structural analog of N,N-dimethyltryptamine (DMT), 5-MeO-DMT is a Schedule 9 prohibited substance under the Poisons Standard.


5-MeO-DMT is not controlled under Belgian law, although DMT is (DMT is controlled under the 1971 UN Convention)


5-MeO-DMT is not controlled under Canadian law.


5-MeO-DMT is controlled in China as a Category I psychotropic substance, illegal to sell, buy, import, export, and manufacture 4-methylmethcathinone as of October 2015


As of December 1, 2004, 5-MeO-DMT is legally restricted to 'medical or scientific purposes'.


5-MeO-DMT was banned in Finland in December 2014. A new government regulation was enacted in Finland that banned over 100 psychoactive chemicals. See Finland's Prohibited Psychoactive Substances: December 19, 2014.


Schedule I / Highest level of control, unable to be prescribed, manufactured, or possessed as of Sep, 1999. (listed as [2-(5-Methoxyindol-3-yl)ethyl]dimethylazan)


5-MeO-DMT became a controlled substance in Greece on Feb 18, 2003


5-MeO-DMT is controlled as a 'designated Substance' (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell


5-MeO-Dmt in any form appears to be legal in Mexico as of 2009 (though this may only extend to personal use)

New Zealand

5-MeO-DMT is Schedule I (Class A) in New Zealand

Russian Federation

5-MeO-DMT became controlled in the Russian Federation starting October, 2011.

South Africa

5-MeO-DMT is NOT classified under the Drug and Drug Trafficking Act No. 140 of 1992 as an "Undesirable Dependence Producing Substance", but could be considered an 'ether' of Bufotenin (5-OH-DMT) or possibly DMT and ethers and esters of the listed substances are also considered controlled.


Controlled in Sweden as of Oct 1, 2004


5-MeO-DMT is Schedule I in Switzerland.


5-MeO-DMT has been controlled since December 2013

United Kingdom

5-MeO-DMT is a Schedule I/Class A drug in the United Kingdom, making it illegal to buy or possess without a license
Dakic V, Nascimento JM, Sartore RC, de Moraes Maciel R, de Araujo DB, Ribeiro S, Martins-de-Souza D, Rehen SK, 2017, This article is a preprint and has not been peer-reviewed, doi:


Dimethyltryptamines are hallucinogenic serotonin-like molecules present in traditional Amerindian medicine (e.g. Ayahuasca, Virola) recently associated with cognitive gains, antidepressant effects and changes in brain areas related to attention, self-referential thought, and internal mentation. Historical and technical restrictions impaired understanding how such substances impact human brain metabolism. Here we used shotgun mass spectrometry to explore proteomic differences induced by dimethyltryptamine (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) on human cerebral organoids. Out of the 6,728 identified proteins, 934 were found differentially expressed in 5-MeO-DMT-treated cerebral organoids. In silico systems biology analyses support 5-MeO-DMT's anti-inflammatory effects and reveal a modulation of proteins associated with the formation of dendritic spines, including proteins involved in cellular protrusion formation, microtubule dynamics and cytoskeletal reorganization. Proteins involved in long-term potentiation were modulated in a complex manner, with significant increases in the levels of NMDAR, CaMKII and CREB, but a reduction of PKA and PKC levels. These results offer possible mechanistic insights into the neuropsychological changes caused by the ingestion of substances rich in dimethyltryptamines
Agurell S, Holmstedt B & Lindgren JE, 1969, 'Metabolism of 5-methoxy-N,N dimethyltryptamine-14C in the rat', Biochemical Pharmacology, vol. 18, no. 12, pp. 2771-2781,,


The metabolism of 5-methoxy-N,N-dimethyltryptamine-14C has been investigated in the rat after i.p. injection (5 mg/kg). About 59–65 per cent of the radioactivity is excreted in the 24 hr urine, 4–9 per cent is eliminated in the faeces and 1 per cent as carbon dioxide during this time. Of the metabolites appearing in the urine 54 per cent is present as 5-methoxyindoleacetic acid, 9 per cent as bufotenine, 23 per cent as bufotenine glucuronide and 14 per cent as 5-hydroxyindoleacetic acid. Considerable differences in the metabolism occurred at high dose levels. 5-Methoxyindoleacetic acid-3H is not demethylated to 5-hydroxyindoleacetic acid.I.p. administered 6-hydroxy-5-methoxy-N,N-dimethyltryptamine-3H is excreted mainly unchanged and to a minor degree as conjugate and as 6-hydroxy-5-methoxyindoleacetic acid.
5-Methoxy-N,N-dimethyltryptamine is not 6-hydroxylated to a detectable degree in vivo and 6-hydroxylation is apparently of no importance for the psychotropic activity of 5-methoxy-N,N-dimethyltryptamine.

Squires RF, 1975, 'Evidence That 5-Methoxy-N, N-Dimethyl Tryptamine Is a Specific Substrate For Mao-A in The Rat: Implications For The Indoleamine Dependent Behavioural Syndrome', Journal of Neurochemistry, vol. 24, no. 1, pp. 47-50, DOI: 10.1111/j.1471-4159.1975.tb07626.x,


A simple method for the separation of 5-hydroxyindoleacetic acid (5-HIAA) and 5-methoxyindoleacetic acid (5-MeOIAA) on columns of non-ionic polystyrene (Amberlite XAD-2) is described. Administration of 5-methoxy-N, N-dimethyl-tryptamine (5-MeODMT) 2 mg/kg i. p. to rats results in a sixfold increase in brain 5-MeOIAA within 15 min. This increase is blocked by the selective inhibitor of MAO-A, clorgyline, but not by the selective inhibitor of MAO-B, deprenyl, indicating that 5-MeODMT is deaminated almost entirely by MAO-A. The apparent 5-MeOIAA concentration in the brains of L-tryptophan loaded rats is not reduced by clorgyline and deprenyl, either singly or in combination, indicating that most of this fluorescence is due to other, unidentified substances. The apparent concentration of 5-HIAA in rat brain, minus 5-MeOIAA, is unaffected by deprenyl and reduced by clorgyline. However, clorgyline and deprenyl in combination reduced 5-HIAA values below those obtained with clorgyline alone. It is concluded that very little 5-MeODMT or other 5-methoxyindoleamines are formed endogenously in rat brain, and that the stereotyped syndrome of hyperactivity and tremors produced in rats by pretreatment with MAO inhibitors and L-tryptophan is dependent on the formation of an N-substituted derivative of 5-HT which is at least partly deaminated by MAO-B to 5-HIAA
Alhaider AA, Hamon, M & Wilcox, GL, 1993, 'Intrathecal 5-methoxy-N, N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors', European Journal of Pharmacology, vol. 249, no. 2, 9, pp. 151-160,


The antinociceptive effects of intrathecally administered 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), a potent 5-HT receptor agonist, were studied in three behavioral tests in mice: the tail-flick test and the intrathecal substance P and N-methyl-D-aspartic acid (NMDA) assays. Intrathecal administration of 5-MeO-DMT (4.6–92 nmol/mouse) produced a significant prolongation of the tail-flick latency. This action was blocked by 5-HT3 and γ-aminobutyric acidA (GABAA) receptor antagonists but not by 5-HT2, 5-HT1A, 5-HT1B or 5-HT1S receptor antagonists. Binding studies indicated that 5-MeO-DMT had very low affinity for 5-HT3 receptors. 5-MeO-DMT inhibited biting behavior while increasing scratching behavior induced by intrathecally administered substance P. The inhibition of biting behavior was antagonized by intrathecal co-administration of 5-HT1B and GABAA receptor ntagonists while 5-HT1A, 5-HT1S, 5-HT2 and 5-HT3 receptor antagonists had no effect. 5-MeO-DMT-enhanced scratching behavior was inhibited by all the antagonists used except ketanserin and bicuculline, suggesting the involvement of 5-HT1A, 5-HT1B, 5-HT1S, 5-HT3 and GABAA receptors. NMDA-induced biting behavior was inhibited by 5-MeO-DMT pretreatment; this action was antagonized by 5-HT1B, 5-HT3 and GABAA receptor antagonists. The involvement of these receptors in 5-MeO-DMT action suggests that it may promote release of 5-HT (5-hydroxytryptamine, serotonin).
Wallach JV, 2009, 'Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception', Medical Hypotheses, vol. 72, no. 1, pp. 91-94,


While the endogenous hallucinogens, N,N-dimethyltryptamine, 5-hydroxy-N,N-dimethyl-tryptamine and 5-methoxy-N,N-dimethyltryptamine, have been acknowledged as naturally occurring components of the mammalian body for decades, their biological function remains as elusive now as it was at the time of their discovery. The recent discovery of the trace amine associated receptors and the activity of DMT and other hallucinogenic compounds at these receptor sites leads to the hypothesis that the endogenous hallucinogens act as neurotransmitters of a subclass of these trace amine receptors. Additionally, while activity at the serotonin 5-HT2A receptor has been proposed as being responsible for the hallucinogenic affects of administered hallucinogens, in their natural setting the 5-HT2A receptor may not interact with the endogenous hallucinogens at all. Additionally 5-HT2A agonist activity is unable to account for the visual altering effects of many of the administered hallucinogens; these effects may be mediated by one of the endogenous hallucinogen trace amine receptors rather than the serotonin 5-HT2A receptor. Therefore, activity at the trace amine receptors, in addition to serotonin receptors, may play a large role in the sensory altering effects of administered hallucinogens and the trace amine receptors along with their endogenous hallucinogen ligands may serve an endogenous role in mediating sensory perception in the mammalian central nervous system. Thus the theory proposed states that these compounds act as true endogenous hallucinogenic transmitters acting in regions of the central nervous system involved in sensory perception
Archer T, Minor BG, Post C, 1985, 'Blockade and reversal of 5-Methoxy-N, N-Dimethyltryptamine-induced analgesia following noradrenaline depletion', Brain Research, vol. 333, no. 1, pp. 55-61,


The acute effects of the 5-hydroxytryptamine agonist, 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT), upon pain sensitivity, using shock titration, tail-flick and hot-plate methods, in noradrenaline- and 5-hydroxytryptamine-depleted rats were examined. Noradrenaline depletion, following the systemic administration of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride (DSP4, 2 × 50 mg/kg, i.p.), caused a reversal of the analgesic effect of 5-MeO-DMT on shock-titration from hypo- to hypersensitivity, and a total blockade of the antinociceptive effect of 5-MeO-DMT upon pain responses in the hot-plate and tail-flick tests. Pretreatment with eitherp-chloroamphetamine (2 × 10 mg/kg) orp-chlorophenylalanine (200, 100, 100 mg/kg), that depletes central 5-hydroxytryptamine stores, failed to alter the analgesia caused by acute 5-MeO-DMT. Strong evidence is provided for the effect of central noradrenaline depletion upon the analgesic effect of the 5-HT agonist. These findings suggest an important tonic influence of the noradrenaline system upon the descending spinal 5-HT pathway in rats.
Van Den Buuse M, Ruimschotel E, Martin S, Risbrough VB, Halberstadt AL, 2011, 'Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT1A receptor knockout mice: Implications for schizophrenia', Neuropharmacology, vol. 61, nos. 1–2, pp. 209-216,


Serotonin-1A (5-HT1A) receptors may play a role in schizophrenia and the effects of certain antipsychotic drugs. However, the mechanism of interaction of 5-HT1A receptors with brain systems involved in schizophrenia, remains unclear. Here we show that 5-HT1A receptor knockout mice display enhanced locomotor hyperactivity to acute treatment with amphetamine, a widely used animal model of hyperdopaminergic mechanisms in psychosis. In contrast, the effect of MK-801 on locomotor activity, modeling NMDA receptor hypoactivity, was unchanged in the knockouts. The effect of the hallucinogen 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) was markedly reduced in 5-HT1A receptor knockout mice. There were no changes in apomorphine-induced disruption of PPI, a model of sensory gating deficits seen in schizophrenia. Similarly, there were no major changes in density of dopamine transporters (DAT) or dopamine D1 or D2 receptors which could explain the behavioural changes observed in 5-HT1A receptor knockout mice. These results extend our insight into the possible role of these receptors in aspects of schizophrenia. As also suggested by previous studies using agonist and antagonist drugs, 5-HT1A receptors may play an important role in hallucinations and to modulate dopaminergic activity in the brain.
Gillin JC, Tinklenberg J, Stoff DM & Wyatt RJ, 1976, '5 Methoxy N,N dimethyltryptamine: behavioral and toxicological effects in animals', Biological Psychiatry, vol. 11, no. 3, pp. 355-8,


These studies indicate that 5 MeO DMT has potent, rapidly appearing effects in the central nervous system. It has fatal effects in sheep at low doses, but not in monkeys, rats, or mice.
Stoff DM, Gorelick DA, Bozewicz T, Bridger WH, Gillin JC & Wyatt RJ, 1978, 'The indole hallucinogens, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), have different effects from mescaline on rat shuttlebox avoidance', Neuropharmacology, vol. 17, no. 12, pp. 1035-40,


The indole hallucinogenic drugs, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), had a different psychopharmacological profile from mescaline on rat shuttlebox avoidance; the differences were strain and/or baseline-dependent. N,N-dimethyltryptamine and 5-MeO-DMT shared dose response disruptive effects with mescaline on avoidance behaviour in two rat strains who were performing the conditioned avoidance response at a high baseline (i.e. during acqusition in Fischer 344s—Experiment 1; on pretrained good performing hooded rats—Experiment 2). N,N-dimethyltryptamine and 5-MeO-DMT were without an effect when the baseline conditioned avoidance response was low (i.e. during acquisition in Zivic-Millers, Hoods or Roman Low Avoiders—Experiment 1; on pretrained poorly performing hooded rats—Experiment 2) but mescaline was facilitatory in these situations. There were strain-related differences in sensitivity to the drugs with Roman High Avoiders insensitive to DMT, 5-MeO-DMT and mescaline, while Fischer 344s were the most sensitive to these three drugs. The relative potency of these three hallucinogens in disrupting avoidance behavior (5-MeO-DMT > DMT > mescaline), in terms of mg/kg paralleled reports of their relative potency on central serotonergic activity. The facilitatory effect produced by mescaline, but not produced by DMT nor 5-MeO-DMT, may be related to the findings that mescaline has a stronger action on the catecholaminergic system than the indoles
Guchhait RB, 1976, 'Biogenesis of 5-methoxy-N,N-dimethyltryptamine in human pineal gland', Journal of Neurochemistry, vol. 26, pp. 187-193, DOI: 10.1111/j.1471-4159.1976.tb04456.x,


The present report provides further insight about the controversial role of MTHF as a methyl donor for indoleamines. Attempts are also made to demonstrate the in vitro formation of 5 MeO DMT from indoleamine precursors by the human pineal extract using SAMe as the methyl donor. The identity of this biosynthetic product is supported by thin layer chromatographic procedures and by carrier crystallization technique.